EP 153 - Christopher Uhde: The Biotech IPO Boom is Over. Now What?

In 2021, biotech IPOs were soaring. Valuations hit record highs. Investors were throwing money at anything that moved.Then… the market crashed. Funding dried up. Growth stalled. Biotech founders and investors were left scrambling.So what really happened? And more importantly—how do you navigate what’s next?📌 In this episode, Christopher Uhde—Senior Pharma & Biotech Equity Analyst at SEB—breaks down the brutal realities of biotech IPOs, investor sentiment, and the high-stakes game of survival in a post-boom world.🎧 Watch now to learn:1️⃣ Why valuations aren’t about science—but about demand. 2️⃣ The biggest mistake biotech founders make after going public. 3️⃣ How to raise capital before you actually need it. 4️⃣ The European biotech advantage—and how to leverage it. 5️⃣ How to attract the right investors and avoid the wrong ones.👤 About Christopher Uhde:Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB, one of Europe’s leading financial institutions. With a PhD in neurodevelopmental systems biology and postdoctoral research in drug discovery, he’s spent years studying the biotech market—from billion-dollar giants to early-stage startups—analyzing their success, failures, and what separates winners from the rest.💡 Quotes to Challenge Your Thinking: 📌 (00:16:29) "Valuation isn’t about science; it’s about demand and the right investors." 📌 (00:49:17) "The power of the right team in biotech can’t be overstated." 📌 (01:13:08) "European startups struggle not from lack of innovation, but from a lack of ownership mindset." 📌 (01:38:39) "The long-term equity story isn’t just about share price—it’s about trust and vision." 📌 (01:50:44) "Biotech isn’t just about breakthrough science—it’s about strategy, trust, and long-term vision."⏰ Timestamps: (00:09:48) IPO Market Realities and Investor Sentiment (00:17:59) Why European biotech should think beyond US listings (00:25:15) The hidden challenges of taking a company public (00:28:45) Preparing for IPO Compliance (00:37:11) Public company leadership demands strategic communication (00:49:17) The power of the right team in biotech (00:52:48) Planning for success in biotech acquisitions (01:13:08) Incentivizing Innovation in Europe (01:23:33) Nordic IPO culture shaping biotech success (01:36:16) Realistic Communication in Biotech (01:50:44) Europe’s Biotech Global Edge🔔 Help Us GrowIf this episode gave you insight, inspiration, or a new perspective—here’s how you can help:📢 Hit SUBSCRIBE, like, and leave a comment. It’s a small action, but it makes a huge difference. Every engagement helps us bring in more top-tier guests, deeper insights, and the conversations that keep you ahead.Right now, we’re in the global top 10%—let’s push for the top 1% together.🎧 Watch now and make sure your biotech strategy is built to last. 🚀Send us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.Support the showJoin the Podcast Newsletter: Link